X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (755) 755
Publication (28) 28
Newsletter (16) 16
Newspaper Article (14) 14
Book Chapter (4) 4
Book Review (3) 3
Conference Proceeding (3) 3
Magazine Article (3) 3
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
linagliptin (694) 694
index medicus (414) 414
humans (354) 354
type 2 diabetes (296) 296
diabetes mellitus, type 2 - drug therapy (269) 269
male (250) 250
diabetes (220) 220
female (185) 185
endocrinology & metabolism (184) 184
dipeptidyl-peptidase iv inhibitors - therapeutic use (174) 174
metformin (156) 156
pharmacology & pharmacy (153) 153
sitagliptin (153) 153
hypoglycemic agents - therapeutic use (152) 152
middle aged (146) 146
double-blind (143) 143
dipeptidyl peptidase-4 inhibitor (141) 141
animals (133) 133
aged (131) 131
glucose (126) 126
dpp-4 inhibitor (114) 114
dipeptidyl-peptidase iv inhibitors - pharmacology (111) 111
safety (109) 109
treatment outcome (107) 107
vildagliptin (106) 106
dipeptidyl-peptidase iv inhibitors - adverse effects (103) 103
glycemic control (103) 103
diabetes mellitus (99) 99
quinazolines - therapeutic use (92) 92
purines - therapeutic use (91) 91
diabetes mellitus, type 2 - blood (90) 90
type 2 diabetes mellitus (89) 89
drug therapy (87) 87
glucagon-like peptide-1 (86) 86
adult (84) 84
efficacy (84) 84
pharmacokinetics (83) 83
analysis (81) 81
hypoglycemic agents - adverse effects (81) 81
linagliptin - therapeutic use (81) 81
saxagliptin (81) 81
dipeptidyl peptidase-4 inhibitors (79) 79
dipeptidyl-peptidase iv inhibitors - administration & dosage (77) 77
research (77) 77
hypoglycemic agents - administration & dosage (76) 76
double-blind method (74) 74
drug therapy, combination (74) 74
risk factors (73) 73
care and treatment (71) 71
diabetes therapy (71) 71
clinical trials (70) 70
quinazolines - pharmacology (69) 69
purines - pharmacology (66) 66
rats (66) 66
blood glucose - drug effects (63) 63
dosage and administration (63) 63
purines - administration & dosage (63) 63
quinazolines - administration & dosage (63) 63
dipeptidyl-peptidase iv inhibitors - pharmacokinetics (62) 62
hypoglycemic agents - pharmacology (62) 62
dextrose (61) 61
hypoglycemia (61) 61
hypoglycemic agents (61) 61
insulin (60) 60
mice (60) 60
peptidase (60) 60
internal medicine (59) 59
purines - adverse effects (59) 59
quinazolines - adverse effects (59) 59
type-2 diabetes-mellitus (59) 59
blood glucose - metabolism (58) 58
dpp-4 inhibitors (58) 58
bi 1356 (56) 56
glycated hemoglobin a - metabolism (55) 55
hyperglycemia (55) 55
mellitus (55) 55
alogliptin (54) 54
linagliptin - pharmacology (52) 52
dipeptidyl peptidase 4 - metabolism (50) 50
oxidative stress (50) 50
purines - pharmacokinetics (50) 50
quinazolines - pharmacokinetics (50) 50
dose-response relationship, drug (48) 48
pharmacodynamics (48) 48
add-on therapy (46) 46
diabetes mellitus, type 2 - complications (46) 46
linagliptin - adverse effects (45) 45
tolerability (45) 45
health aspects (43) 43
medicine, general & internal (43) 43
randomized controlled trials as topic (43) 43
glycosylated hemoglobin (42) 42
medicine & public health (42) 42
metformin - therapeutic use (42) 42
renal impairment (41) 41
medicine, research & experimental (40) 40
complications and side effects (39) 39
hypoglycemic agents - pharmacokinetics (39) 39
inflammation (39) 39
beta-cell function (38) 38
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (760) 760
French (7) 7
Spanish (7) 7
Czech (6) 6
Japanese (6) 6
Hungarian (4) 4
Russian (4) 4
Chinese (3) 3
German (1) 1
Korean (1) 1
Persian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Molecules, ISSN 1420-3049, 08/2016, Volume 21, Issue 8, pp. 1041 - 1041
Journal Article
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, ISSN 0946-1965, 04/2017, Volume 55, Issue 4, pp. 355 - 367
Objective: This relative bioavailability study compared a fixed-dose combination (FDC) tablet of empaglifiozin 25 mg/linagliptin 5 mg with the corresponding... 
empagliflozin | crossover trial | DIPEPTIDYL PEPTIDASE-4 INHIBITORS | linagliptin | bioavailability | GLUCOSE | dissolution | PHARMACOLOGY & PHARMACY | fixed-dose combination | FOOD | Glucosides - blood | Linagliptin - administration & dosage | Benzhydryl Compounds - administration & dosage | Tablets | Area Under Curve | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Humans | Linagliptin - pharmacokinetics | Middle Aged | Linagliptin - adverse effects | Biological Availability | Male | Metabolic Clearance Rate | Glucosides - pharmacokinetics | Benzhydryl Compounds - blood | Healthy Volunteers | Hypoglycemic Agents - blood | Linagliptin - blood | Benzhydryl Compounds - adverse effects | Hypoglycemic Agents - administration & dosage | Adult | Female | Benzhydryl Compounds - pharmacokinetics | Glucosides - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - blood | Hypoglycemic Agents - pharmacokinetics | Administration, Oral | Sodium-Glucose Transporter 2 - metabolism | Solubility | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Cross-Over Studies | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Glucosides - administration & dosage | Kidney Tubules, Proximal - metabolism | Hypoglycemic Agents - adverse effects | Drug Combinations | Germany | Kidney Tubules, Proximal - drug effects | Therapeutic Equivalency | Bioavailability | Food
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 01/2019, Volume 21, Issue 1, pp. 136 - 145
Journal Article
Journal Article
Cardiovascular Diabetology, ISSN 1475-2840, 04/2018, Volume 17, Issue 1, pp. 59 - 15
Journal Article
Cardiovascular Diabetology, ISSN 1475-2840, 03/2018, Volume 17, Issue 1, pp. 39 - 15
Background: Cardiovascular (CV) outcome trials in type 2 diabetes (T2D) have underrepresented patients with chronic kidney disease (CKD), leading to... 
Treatment outcome | Diabetes mellitus, type 2 | Dipeptidyl-peptidase IV inhibitors | Diabetic nephropathies | Linagliptin | Research design | Cardiovascular diseases | Clinical trial, phase IV | KIDNEY-DISEASE | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | CARDIAC & CARDIOVASCULAR SYSTEMS | type 2 | GFR DECLINE | Diabetes mellitus | phase IV | HEART-FAILURE | SITAGLIPTIN | DPP-4 | END-POINT | ENDOCRINOLOGY & METABOLISM | Clinical trial | POOLED ANALYSIS | CKD | EPIDEMIOLOGY | Kidney Failure, Chronic - mortality | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Cardiovascular Diseases - drug therapy | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Linagliptin - adverse effects | Diabetic Nephropathies - drug therapy | Male | Linagliptin - therapeutic use | Diabetic Nephropathies - diagnosis | Cause of Death | Renal Insufficiency, Chronic - drug therapy | Glomerular Filtration Rate - drug effects | Time Factors | Cardiovascular Diseases - mortality | Renal Insufficiency, Chronic - mortality | Female | Renal Insufficiency, Chronic - diagnosis | Kidney - physiopathology | Cardiovascular Diseases - diagnosis | Kidney Failure, Chronic - physiopathology | Kidney - drug effects | Double-Blind Method | Risk Factors | Treatment Outcome | Biomarkers - blood | Renal Insufficiency, Chronic - physiopathology | Disease Progression | Diabetic Nephropathies - mortality | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - diagnosis | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - mortality | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Research Design
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2016, Volume 11, Issue 12, p. e0167853
Background/aims Dipeptidyl peptidase 4 (DPP4) inhibitors improve glycemic control in type 2 diabetes, however, their influence on the retinal neurovascular... 
PATHWAYS | CELLS | OXIDATIVE STRESS | ACTIVATION | LIRAGLUTIDE | RECEPTOR AGONISTS | INTERLEUKIN-1-BETA | MULTIDISCIPLINARY SCIENCES | BIOLOGY | METHYLGLYOXAL | DEGENERATION | Hypoglycemic Agents - therapeutic use | Diabetic Retinopathy - drug therapy | Dipeptidyl Peptidase 4 - metabolism | Hypoglycemic Agents - pharmacokinetics | Glucagon-Like Peptide 1 - metabolism | Pericytes - drug effects | Rats, Wistar | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Linagliptin - pharmacokinetics | Pericytes - metabolism | Rats | Male | Linagliptin - therapeutic use | Retinal Ganglion Cells - metabolism | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Diabetic Retinopathy - metabolism | Pyruvaldehyde - metabolism | Diabetic Retinopathy - prevention & control | Animals | Caenorhabditis elegans - drug effects | Blood Glucose - metabolism | Retinal Ganglion Cells - drug effects | Diabetic retinopathy | Blood sugar | Linagliptin | Dosage and administration | Research | Drug therapy | Health aspects | Immunohistochemistry | Plasma | Neuroprotection | Retinopathy | Peptides | Laboratories | Retina | Glucose | Proteins | Hyperglycemia | Catalase | Actin | Rodents | Heme | Interleukin 1 | Capillaries | Diabetes mellitus (non-insulin dependent) | Enzyme-linked immunosorbent assay | Peptidase | Cytokines | Intercellular adhesion molecule 1 | Glial fibrillary acidic protein | Diabetes mellitus | Heme oxygenase (decyclizing) | CXCR4 protein | Microglia | Polymerase chain reaction | Oxygenase | Retinal ganglion cells | Pericytes | Nuclei (cytology) | Microvasculature | Diabetes | Morphometry | Pyruvaldehyde | Apoptosis
Journal Article